- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Steven D'Amato, RPh: Adoption of Biosimilars
Steven D’Amato, RPh, executive director and clinical pharmacy specialist at New England Cancer Specialists, explains the factors that he feels will impact adoption of biosimilars.
Transcript:
Do you see biosimilars being used more in the future?
The use of biosimilars coming to the market will be challenging. As you know, biosimilars take a lot of research and development to develop the biosimilar, so the cost savings are probably not going to be as dramatic as some people may expect. I think biosimilars will have a challenge when going up against the branded product. The reason I say that is, number 1, they’ll have to be, certainly, price-advantaged to switch to a biosimilar from a branded product, but there are other things that go into product delivery, and that can be patient assistance programs. I believe that biosimilars will have to have the same programs in place as the brands do for people to embrace their products and bring them on board.
I would say that certainly the clinical data that we’ll review will solidify our use of the biosimilars—I think they’ll be used—[but] I think there’s going to be a price break point that we [will] need to achieve widespread adoption of biosimilars. I think you’re going to need to have really significant cost reductions for practices to switch to biosimilars, and we’ll have to see where that goes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
